Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion.
Authors:
Journal: Journal of thrombosis and thrombolysis
Publication Type: Journal Article
Date: 2015
DOI: 10.1007/s11239-014-1098-x
ID: 25017632
Abstract
The no-reflow phenomenon occurs when an epicardial coronary artery is reopened following myocardial infarction, but portions of the intramural microvasculature fail to reperfuse. One potential mechanism for this is the presence of fibrin tactoids. In addition, some recent studies have suggested that dabigatran treatment may be associated with increased incidence of myocardial infarction. Our aim was to investigate the effect on myocardial infarct size and no-reflow in an acute model of ischemia/reperfusion. Anesthetized, open-chest rabbits were randomly assigned to receive dabigatran (Dab, 0.5 mg/kg bolus + infusion, 0.15 mg/kg/h, IV, n = 11) or vehicle (Veh, n = 11) 15 m before a 30-m coronary artery occlusion and during 2.5 h of the 3 h reperfusion procedure. At the end of the reperfusion period, infarct size (% risk zone) and no-reflow defect were measured. The ischemic risk zone (% of left ventricle) was similar in groups, 24 % in Dab and 25 % in Veh. Necrosis was neither reduced nor increased by Dab treatment; expressed as a percentage of the risk region, infarct size was 30 ± 4 % in Dab and 28 ± 5 % in Veh, p = 0.76. The extent of no-reflow was comparable, expressed either as a percent of the risk region (19 ± 3 %, Dab and 18 ± 3 %, Veh) or as a percent of the necrotic zone (67 ± 8 % Dab and 65 ± 10 % Veh). Dab treatment had no effect on heart rate or blood pressure. Dabigatran treatment did not prevent or ameliorate the no-reflow phenomenon, suggesting that fibrin does not play a major role in the development of microvascular obstruction. Dabigatran did not exacerbate myocardial infarct size.
Chemical List
- Antithrombins|||Benzimidazoles|||beta-Alanine|||Dabigatran
Reference List
- J Clin Invest. 1974 Dec;54(6):1496-508|||Int Angiol. 2012 Aug;31(4):330-9|||J Thromb Thrombolysis. 2013 Feb;35(2):295-301|||J Am Coll Cardiol. 2000 Oct;36(4):1202-9|||J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):60-7|||Ann Plast Surg. 2014 Feb;72(2):253-60|||Ann Thorac Surg. 2003 Feb;75(2):S649-55|||Curr Vasc Pharmacol. 2014;12(6):893-902|||Am J Cardiol. 2007 Feb 15;99(4):442-5|||Ital Heart J. 2005 Jun;6(6):447-52|||BMJ Open. 2012 Oct 06;2(5):|||Am J Physiol. 1997 Jul;273(1 Pt 2):H220-7|||Circulation. 2008 Jun 17;117(24):3152-6|||Acute Card Care. 2009;11(2):69-76|||Heart. 2002 Feb;87(2):162-8|||Circulation. 2012 Feb 7;125(5):669-76|||Am J Cardiol. 2013 Dec 15;112(12):1973-9|||J Neurosci. 1999 Dec 15;19(24):10898-907|||Eur Surg Res. 2003 Sep-Oct;35(5):417-24|||Shock. 2014 Feb;41(2):166-71|||J Am Coll Cardiol. 2013 Jun 4;61(22):2264-73|||J Thromb Haemost. 2007 Jun;5(6):1237-42|||Arch Intern Med. 2012 Mar 12;172(5):397-402|||Catheter Cardiovasc Interv. 2012 Jun 1;79(7):1083-9|||Recent Adv Stud Cardiac Struct Metab. 1975;10:463-74